PDS Biotechnology (PDSB) Stock: Buy, Sell, or Hold?
PDSB - PDS Biotechnology Corporation Common Stock
$0.75
0.04 (6.00%)
â˛
5d:
-6.1%
30d:
+253.07%
90d:
-11.54%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When PDSB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PDSB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PDSB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PDSB is currently trading at $0.75, which is considered slightly high relative to its 30-day fair value range of $0.23 to $0.79.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.70, while resistance sits at $0.99. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: PDSB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.75 (+534.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.70, while resistance sits at $0.99. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: PDSB scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.75 (+534.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.23 -
$0.79
Company Quality Score
25/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: Strong upward momentum (+6.0%)
- BULLISH: Trading 534.6% below Wall St target ($4.75)
- WARNING: Composite score 25/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.23 -
$0.79
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.70
Resistance Level
$1.00
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.06
Wall Street Target
$4.75
(+534.6%)
Share & Embed Analysis
Last updated: October 03, 2026 6:33 PM ET
Data refreshes hourly during market hours. Next update: 7:33 PM
Data refreshes hourly during market hours. Next update: 7:33 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PDSB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
